Earnings Material −

GLG Life Tech Corporation Reports 2025 Annual & Fourth Quarter Financial Results

Tagline: GLG Life Tech Deepens Losses as Stevia Demand Craters Amid Insolvency Fears

By The Northwire Desk — AI Analysis Apr 30, 2026 · 20:55 GLG GLG LIFE TECH CORPORATION J

Executive Summary

The most recent release (April 30, 2026) covers the full year and Q4 2025 financial results.
Revenue for Q4 2025 was $2.1 million, representing a 48% decline year-over-year compared to $4.0 million in Q4 2024.
Full Year 2025 revenue was $10.3 million, down 29% from $14.6 million in 2024.
Net Loss for Q4 2025 surged to $22.9 million, a significant deterioration from the $5.1 million loss recorded in Q4 2024.
Full Year 2025 net loss was $7.5 million, an improvement over the $16.6 million loss in 2024, primarily due to one-time gains from asset dispositions recognized earlier in the year (Q3).
Gross profit margins contracted to 13% in Q4 and 14% for the full year, down from 15% and 17% respectively.
The company completed the transfer of its Runhai subsidiary to a third party to reduce regulatory risk and debt exposure.
Operations have shifted to a contract manufacturing model via Qingdao Honghongyuan Health Industry Technology Co., Ltd (HHY).
Management explicitly noted ongoing cash flow constraints and risks related to insolvency despite positive EBITDA trends, citing significant interest charges.
The company is preparing a submission to the NEX exchange to resume trading following the lifting of a cease-trade order in May 2025.

Material Impact

Operational Deterioration: While the full-year loss improved due to one-time asset sales, the Q4 operational results are alarming. A 48% revenue drop and a quadrupling of quarterly net losses ($5.1M to $22.9M) indicate core business failure that asset sales cannot mask indefinitely.
Liquidity Crisis: The explicit mention of "insolvency risks" in the April 2026 release, following similar warnings in November 2025, suggests no meaningful progress has been made in securing permanent capital or stabilizing cash flows over a six-month period.
Trading Uncertainty: Despite the cease-trade order being lifted in May 2025 (per Nov news), the April 2026 update states they are still "preparing a submission" to NEX. This delay of nearly a year since delisting from TSX raises concerns about regulatory compliance and market access.
Margin Compression: Gross margins shrinking alongside revenue indicates pricing power is non-existent in the stevia/monk fruit markets, exacerbated by competitive pressures noted by management.

GLG · Price

Company Overview

Company: GLG Life Tech Corporation focuses on natural sweeteners, specifically stevia and monk fruit extracts.
Flagship Project: Historically relied on manufacturing facilities in China (Runhai/Runde subsidiaries).
Current Status: Transitioning away from direct ownership of Chinese manufacturing assets to a contract manufacturing model via HHY to mitigate geopolitical and regulatory risks.
Market Position: Facing significant competitive price pressure in the stevia market, leading to revenue declines.

More from GLG LIFE TECH CORPORATION J